Limb-Girdle Muscular Dystrophy (LGMD) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Limb-Girdle Muscular Dystrophies (LGMD) are a clinically heterogeneous group of disorders presenting a spectrum of disease severity ranging from severe childhood-onset muscular dystrophy to adult-onset dystrophy. LGMDs includes both dominant and recessive forms. With the current classification system for LGMDs, 33 recessively (LGMD2) and dominantly (LGMD1) inherited forms of LGMD have now been identified. Interestingly, two LGMD types, with defects in the calpain three and desmin proteins, exist in both recessive and dominant forms. More than 90 percent of all people with the disease have any recessively inherited conditions called Type 2 (read more about inheritance patterns under the heading Heredity). LGMD typically manifests itself during childhood or early adulthood. Babies, young children, and the elderly, on the other hand, can be affected. The severity of the disease varies depending on the subtype. Some subtypes are mild, causing only muscle pain. Others can result in increased weakness and mobility loss.

 

The prevalence of Limb-Girdle Muscular Dystrophies (LGMD) cases varies from 15,750 to 18,500 patients in the USA.

 

The competitive landscape of Limb-Girdle Muscular Dystrophy (LGMD) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Limb-Girdle Muscular Dystrophy (LGMD) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Limb-Girdle Muscular Dystrophy (LGMD) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Limb-Girdle Muscular Dystrophy (LGMD) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ATA-100           Atamyo Therapeutics     Phase 1

2          Deflazacort       PTC Therapeutics         Phase 3

3          ATYR1940        aTyr Pharma, Inc.         Phase 2

4          LION-101          Asklepios Biopharmaceutical, Inc.          Phase 2

5          SRP-9003         Sarepta Therapeutics, Inc.         Phase 1

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033